Alife Health Receives FDA Clearance for AI Fertility Tool Embryo Predict

May 28, 2026
Alife Health has received FDA clearance for Embryo Predict, an AI system that assists fertility specialists in evaluating embryos for transfer during IVF procedures.

Alife Health has received clearance from the U.S. Food and Drug Administration (FDA) for its artificial intelligence system Embryo Predict, announced in a press release. The tool assists fertility specialists in assessing and selecting embryos for transfer during in vitro fertilization.

Embryo Predict uses AI to analyze images of embryos and generate a score based on patterns learned from thousands of embryo outcomes across global clinics and patient profiles. It integrates with existing microscopes and imaging systems in fertility labs without requiring new hardware.

The FDA clearance followed a prospective, randomized clinical trial conducted at seven U.S. centers, involving 440 patients. The trial compared embryo selection assisted by AI with standard evaluation methods.

The system is designed to analyze images of Day 5, 6, and 7 blastocyst-stage embryos considered suitable for transfer. It provides additional information to support embryologists in selecting embryos for transfer or freezing. Embryo Predict also holds CE Mark certification and is commercially available in the United States, Europe, and the United Kingdom.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

05/28
Sino Biological Supports Tencent AI Lab Protein Design Study Published in Nature Communications
05/28
Sirona Medical and Everlight Radiology Form Five-Year Global Partnership
05/28
CVS Health Expands Use of Salesforce Agentforce for AI Call Centers
05/28
DeepIntent Partners with Lane4.io to Expand Programmatic Access to Point-of-Care Media
05/28
Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson’s and Rare Epilepsy Research

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like